Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 79162, held by Invagen Pharms. Topiramate.
As of Nov 15, 2026, ANDA 79162 (Topiramate), held by Invagen Pharms, was first approved by FDA on Mar 27, 2009, with 12 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial- onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2009 | Original application | Approved |
| Topiramate25MG · tablet;oral | Topiramate | Rx |
| Topiramate50MG · tablet;oral | Topiramate | Rx |
| Topiramate100MG · tablet;oral | Topiramate | Rx |
| Topiramate200MG · tablet;oral | Topiramate | Rx |
| Apr 24, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 24, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 24, 2026 | Supplement 16Labeling · Standard review | Approved | None posted |
| Apr 24, 2026 | Supplement 21Labeling · Standard review | Approved | None posted |
| Apr 24, 2026 | Supplement 24Labeling · Standard review | Approved | None posted |
| Apr 24, 2026 | Supplement 26Labeling · Standard review | Approved | None posted |
| Apr 24, 2026 | Supplement 27Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Supplement 4Labeling | Approved | None posted |
| Dec 1, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 24, 2011 | Supplement 3Labeling | Approved | None posted |
| Dec 28, 2010 | Supplement 2Labeling | Approved | None posted |
| Jan 27, 2010 | Supplement 1Labeling | Approved | None posted |
| Mar 27, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters